China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Olink reported before the opening of the market Monday that its Q4 revenues rose 61 percent.

A globally renowned expert in autoimmune diseases and systemic lupus erythematosus (SLE) at the University of Houston has identified potential biomarkers for neuropsychiatric symptoms of lupus.

The continuous outbreak of the 2021 epidemic has drawn attention to the issue of upstream raw materials in China's IVD industry.

Bruker on Friday reported that its fourth quarter revenues were up 9 percent year over year, driven by growth across almost all of the firm's business segments.

Along with the development of new therapies, advances in technologies that enable earlier diagnosis of cancer are critical to improve patient outcomes.

On January 30, China Telecom Medical Health Technology Co., Ltd. was established with a registered capital of CNY 200 million.

Illumina reported after the close of the market on Thursday that its fourth quarter 2021 revenues rose 26 percent year over year, narrowly beating its own forecast last month of 25 percent growth.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced financial results for the fourth quarter and year ended December 31, 2021.

Jiangsu Mole Bioscience obtained the approval of the Helicobacter pylori 23S rRNA gene and gyrA gene mutation test kit (fluorescence PCR method) by NMPA. This kit is the first product in China that can simultaneously detect clarithromycin and levofloxacin resistance genes.

Roche on Thursday reported a 29 percent year-over-year increase in sales in its diagnostics division for full-year 2021, driven by momentum in the base business and continued demand for COVID-19 testing.